Katy Warner / Wikimedia Commons

Steven Collis, longtime chief executive officer of drug distributor AmerisourceBergen, made more than $32 million in his company's 2016 fiscal year, per a federal filing released Friday. That total includes the actual realized gains from Collis' stock options, not the estimated fair value, as well as his salary and bonuses.

For Collis, his payday was actually lower than the year before, when he took home more than $34 million.

Why it matters: Business was good for AmerisourceBergen, which delivers drugs to pharmacies, hospitals, clinics and other health care sites and may be the largest company you've never heard of. The company netted a $1.4 billion profit on $147 billion of revenue last year. That means AmerisourceBergen is twice as big as companies like Procter & Gamble or Target.

Similar to pharmacy benefit managers, drug distributors thrive on higher drug prices, which has stoked public outrage and may invite federal regulation. They also don't get nearly the same scrutiny as the drug companies that list the prices.

AmerisourceBergen was upfront with investors in November about what will happen if drug prices get targeted. "If the frequency or rate of branded and generic pharmaceutical price increases slows, our results of operations could be adversely affected," the company said in its annual 10-K filing.

Go deeper

Mike Allen, author of AM
35 mins ago - Politics & Policy

Trump-Biden venom on display during final debate

Photos: Brendan Smialowski/AFP via Getty Images; Jim Watson/AFP via Getty Images

Joe Biden twice referred to President Trump as "this guy," and Trump called the former vice president's family "like a vacuum cleaner" for foreign money.

Why it matters: The personal venom — during Thursday's final presidential debate, in Nashville — was a reminder that even during a more normal debate, nothing this year is normal.

Dave Lawler, author of World
2 hours ago - World

Special report: Trump's hopes of nuclear deal with Putin come down to the wire

Illustration: Lazaro Gamio/Axios

A surprise offer from Vladimir Putin has the U.S. and Russia once again circling a potential pre-election nuclear deal.

The big picture: The last treaty constraining the U.S. and Russia, New START, is due to expire on Feb. 5, 2021, two weeks after the next U.S. presidential inauguration. For the first time since the height of the Cold War, the nuclear guardrails could come off.

The cliffhanger could be ... Georgia

Illustration: Sarah Grillo/Axios

It hasn't backed a Democrat for president since 1992, but Georgia's changing demographics may prove pivotal this year — not only to Trump v. Biden, but also to whether Democrats take control of the Senate.

Why it matters: If the fate of the Senate did hinge on Georgia, it might be January before we know the outcome. Meanwhile, voters' understanding of this power in the final days of the election could juice turnout enough to impact presidential results.